Money Lancer
Equity: Sectoral-Pharma and Healthcare
Nippon India Mutual Fund
Nippon India Mutual Fund · Equity: Sectoral-Pharma and Healthcare

Nippon India Pharma Fund-Growth Plan-Growth Option

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies. There is no assurance that the investment objective of the Scheme will be achieved.

EquityBenchmark · BSE Healthcare TRITER · 2.32%Inception · 01-06-2004
NAV
542.65
+1.99% · as of 14-05-2026
Since inception
19.95%
CAGR
Benchmark (inception)
14.86%
CAGR
Fund size
₹84 Cr
AUM
Expense ratio
2.32%
30-04-2026
Performance

Returns vs benchmark & category

Since inception: +19.95% CAGR vs benchmark +14.86%.

Portfolio

Where the money is invested

Top holdings

SUN PHARMACEUTICAL INDUSTRIES LTD. EQ NEW F.V. RE.1/-13.92%
LUPIN LIMITED EQ NEW F.V. RS.2/-8.45%
DIVIS LABORATORIES LIMITED EQ NEW RS. 2/-6.41%
Dr. Reddys Laboratories Ltd5.96%
CIPLA LIMITED EQ NEW FV RS.2/-5.42%
APOLLO HOSPITALS ENTERPRISE LIMITED EQ NEW F.V. RS.5/-5.15%
MEDPLUS HEALTH SERVICES LIMITED EQ NEW FV RS.2/-3.86%
AJANTA PHARMA LIMITED EQ NEW FV RS. 2/-3.36%
MAX HEALTHCARE INSTITUTE LIMITED EQ3.24%
VIJAYA DIAGNOSTIC CENTRE LIMITED EQ NEW FV Re.1/-3.15%

Sector allocation

Healthcare95.59%
Consumer Services3.86%
Riskometer
LowVery High
Very High

What if you'd SIP'd here?

@ 19.9% p.a.
₹10,000
10 years
Projected value
₹38,11,256
Invested: ₹12,00,000
Gained: ₹26,11,256
Start this SIP →

Illustration based on fund's since-inception return. Past performance is not indicative of future returns.

Risk Analysis

How this fund manages risk

Fund manager
S
Sailesh Raj Bhan
Manager since fund inception data not available
ISIN & identifiers
AMFI code
102431
ISIN (Growth)
INF204K01968
ISIN (Div Re-inv)
Status
Open Ended Schemes
Peers

Other Equity: Sectoral-Pharma and Healthcare funds

Want a personalised recommendation?

Our team will tell you whether this fund fits your goals, allocation and risk profile — and suggest peers if it doesn't.

Chat with us